INVENTION DISCLOSURE

Title: Novel Therapeutic Compound for Autoimmune Disorders
Inventors: Dr. Emily Chen, Dr. Robert Johnson
Disclosure Date: January 5, 2024

TECHNICAL FIELD:
Pharmaceutical compositions for treating autoimmune disorders

BACKGROUND:
Current treatments have significant side effects and limited efficacy.

SUMMARY OF INVENTION:
Novel compound (designated BT-2024) that selectively modulates 
immune response with improved safety profile.

KEY ADVANTAGES:
1. 10x more selective than existing treatments
2. Oral bioavailability >80%
3. Once-daily dosing
4. Reduced immunosuppression side effects

DEVELOPMENT STATUS:
- Preclinical studies: Complete
- Phase I trials: Initiated
- Patent filed: January 15, 2025

COMMERCIAL POTENTIAL:
- Target market: $15B autoimmune market
- Peak sales estimate: $2B annually
